For retaspimycin, an inhibitor of heat-shock protein 90 (Hsp90), Infinity is enrolling for a Phase II trial in non-small-cell lung cancer in patients with a history of smoking

A July 2012 study completed by the Tufts Center for the Study of Drug Development (TCSDD) found that cancer patients in the U.S...It plans to examine potential new models designed to improve the efficiency and effectiveness of cancer prevention, early detection and treatment and maintain the quality of cancer care while reducing the financial burden of cancer for patients, health systems and society

The study showed T-cell responses against one or more of seven cancer-specific antigens in 61 percent (11/18) of evaluable cancer patients, and 89 percent (8/9) of patients with breast or ovarian cancer

A July 2012 study completed by the Tufts Center for the Study of Drug Development (TCSDD) found that cancer patients in the U.S...It plans to examine potential new models designed to improve the efficiency and effectiveness of cancer prevention, early detection and treatment and maintain the quality of cancer care while reducing the financial burden of cancer for patients, health systems and society

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., said it completed the first cohort in a Phase I/II trial testing lead compound trans sodium crocetinate (TSC) in newly diagnosed primary brain cancer patients

GenSpera Inc., of San Antonio, Texas, said the FDA cleared the firm to start a Phase II trial of lead compound G-202 in prostate cancer patients who have failed prior hormonal therapy

One involves a Phase II trial of cabozantinib in non-small-cell lung cancer patients who have tested positive for gene fusions that activate RET, conducted by Naiyer Rizvi, a lung cancer specialist at Memorial Sloan Kettering Cancer Center

Beta Blockers Can Prevent Metastases Stress reduction in cancer patients has the reputation of being a touchy-feely approach...The authors concluded that treating breast cancer patients with either beta blockers or RANKL inhibitors such as Xgeva or Prolia (both denosumab, Amgen Inc.) could "inhibit both the early colonization of bone by metastatic breast cancer cells and the initiation of the 'vicious cycle' of bone destruction induced by these cells

The molecule, which gained European approval in 2009 for treating malignant ascites (abdominal fluid) in cancer patients, targets the T-cell antigen CD3 and epithelial cell adhesion molecule (EpCAM; CD326

The molecule, which gained European approval in 2009 for treating malignant ascites (abdominal fluid) in cancer patients, targets the T-cell antigen CD3 and Epithelial cell adhesion molecule (EpCAM; CD326

Sanofi SA, of Paris, informed the European Medicines Agency that it is withdrawing its application for marketing authorization for Mulsevo (semuloparin sodium) to prevent venous thromboembolism in certain cancer patients

In a trial of HER2-negative breast cancer patients, the drug led to median progression-free survival (PFS) of 8.3 months when administered in combination with capecitabine, vs. 7.5 months for those on capecitabine alone...The company previously reported that in pancreatic cancer patients the drug improved median overall survival to 12.5 months when administered in combination with gemcitabine, vs. 9.9 months for those on gemcitabine only

Sanofi SA, of Paris, informed the European Medicines Agency that it is withdrawing its application for marketing authorization for Mulsevo (semuloparin sodium) to prevent venous thromboembolism in certain cancer patients

In a trial of HER2-negative breast cancer patients, the drug led to median progression-free survival of 8.3 months when administered in combination with capecitabine, vs. 7.5 months for those on capecitabine alone...The company previously reported that in pancreatic cancer patients the drug improved median overall survival to 12.5 months when administered in combination with gemcitabine, vs. 9.9 months for those on gemcitabine only

Audeo found in a randomized Phase II trial of HA-Irinotecan (Camptosar, Pfizer Inc.) that progression-free survival was doubled in colon cancer patients receiving the HA-Irinotecan vs...The trial is being carried out at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Australia and will enroll 40 first-line small-cell lung cancer patients

cancer patients, and 89% of those with breast or

aza-anthracenedione Aggressive non-Hodgkin B-cell lymphomas Phase III data were the basis for conditional marketing authroziation in the European Union 6/1/12 Genentech Inc. (South San Francisco; part of the Roche Group) Perjeta Pertuzumab HER2-positive metastatic breast cancer Patients lived significantly longer when treated with the combination of Perjeta, Herceptin and docetaxel chemotherapy, compared to Herceptin and docetaxel alone in the Phase III study 6/25/12 Genta Inc. (Berkeley Heights

cancer patients with muscle wasting by improving physical function 6/27/12 Infinity Pharmaceuticals Inc. (Cambridge, Mass.) IPI-926 Saridegib Chondro-sarcoma Interim Phase II data indicated the treatment was similar to placebo and the trial would not meet its primary endpoint

alone, according to Tesaro, which estimated that 70 percent to 80 percent of cancer patients treated with current standard of care for CINV would benefit from treatment with an NK-1 receptor antagonist...The company also has niraparib, formerly known as MK-4827, an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor that has undergone a Phase 1 trial in cancer patients as a monotherapy and is under evaluation by Merck & Co